Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
21-Sep-2026 | 369.95 | 387.05 | 360.4 | 385.15 | 1,09,731 | 1,36,64,38,373.25 | 16,10,952 |
22-Sep-2026 | 385.15 | 385.85 | 373.6 | 377.5 | 19,766 | 15,98,11,195.25 | 2,00,116 |
23-Sep-2026 | 379.4 | 386.85 | 375.15 | 381.85 | 12,673 | 14,11,13,494.35 | 1,44,607 |
24-Sep-2026 | 380 | 384.9 | 378.1 | 380.35 | 11,706 | 8,78,36,378.35 | 1,04,881 |
25-Sep-2026 | 380.35 | 381.85 | 376.95 | 378.7 | 9,035 | 6,73,65,898.8 | 93,806 |
28-Sep-2026 | 380 | 380 | 374 | 376 | 11,927 | 10,21,36,313.5 | 1,57,021 |
29-Sep-2026 | 376 | 376.95 | 365 | 367.2 | 30,455 | 21,54,20,017.65 | 2,80,642 |
30-Sep-2026 | 367.2 | 373.3 | 363.1 | 365.3 | 21,324 | 12,69,11,968.9 | 2,01,268 |
01-Oct-2026 | 365.3 | 365.3 | 353.3 | 361.3 | 26,200 | 19,03,68,561.75 | 2,85,826 |
05-Oct-2026 | 361 | 364.45 | 355.55 | 357.4 | 18,166 | 11,74,14,704.9 | 1,66,211 |
06-Oct-2026 | 357.4 | 364 | 355.55 | 363.2 | 17,381 | 11,49,88,378.95 | 1,91,574 |
07-Oct-2026 | 362 | 362 | 357.8 | 360.3 | 13,109 | 14,91,80,886.8 | 2,64,927 |
08-Oct-2026 | 363.7 | 363.7 | 345.2 | 346 | 15,954 | 11,67,77,151.75 | 2,04,121 |
09-Oct-2026 | 346.1 | 351.95 | 344.45 | 347.4 | 22,870 | 13,22,26,073.45 | 2,45,813 |
12-Oct-2026 | 358.5 | 376.8 | 353.95 | 371.95 | 1,12,882 | 1,36,73,10,834.55 | 8,28,269 |
13-Oct-2026 | 374.05 | 381 | 366.15 | 379.55 | 31,886 | 23,75,99,787 | 2,57,885 |
14-Oct-2026 | 382 | 394.15 | 378.25 | 390.5 | 45,799 | 39,06,59,798.6 | 5,23,790 |
15-Oct-2026 | 390.55 | 397.9 | 382.4 | 384.2 | 36,591 | 32,93,98,851.2 | 4,33,266 |
16-Oct-2026 | 385 | 390 | 382.5 | 386.1 | 20,147 | 13,83,20,745.3 | 1,76,191 |
The outcome of the inspection has been classified as “Voluntary Action Indicated” or VAI.
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
